Review
| Autor: | Leylagül Kaynar, Filiz Vural, Ramazan Esen, Seval Akpinar, Ismet Aydogdu, Mehmet Ali Erkurt, Hakan Goker, Fatih Demirkan, Emre Tekgündüz, Fusun Gediz, Engin Kelkitli, Orhan Ayyildiz, Mehmet Yilmaz, Serdal Korkmaz, Volkan Karakuş |
|---|---|
| Přispěvatelé: | Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Ayyıldız, Orhan |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Thrombotic microangiopathy Consensus Turkey Thrombotic thrombocytopenic purpura Therapeutic Plasma Exchange Presumptive diagnosis Hemolytic Uremic Syndrome urologic and male genital diseases Gastroenterology Adamts13 Young Adult Therapeutic plasma exchange Thrombotic Microangiopathy hemic and lymphatic diseases Internal medicine medicine Humans Hemolytic uremic syndrome Clinical significance Prospective Studies Registries Pathological Aged Experience Hematology Hematopoietic cell transplantation Adult patients Plasma Exchange business.industry Thrombocytopenic Purpura Thrombotic Microangiopathies Thrombotic Thrombocytopenic Purpura Middle Aged medicine.disease Hemolytic-Uremic Syndrome Female business |
| Popis: | Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity 10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18?74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier Ltd Alexion Pharmaceuticals: 100064 The present study was designed as an investigator initiated trial (IIT) and sponsored by Alexion Pharmaceuticals (Tracking number: 100064) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|